Understanding the Fibromyalgia Syndrome

被引:0
作者
Rao, Srinivas G. [1 ]
Gendreau, Judith F. [1 ]
Kranzler, Jay D. [1 ]
机构
[1] Cypress Biosci Inc, San Diego, CA 92121 USA
关键词
fibromyalgia; FMS; pain; chronic pain; dorsal horn; neuroendocrine; controlled trials; transporter binding; sleep; PITUITARY-ADRENAL AXIS; POSITRON-EMISSION-TOMOGRAPHY; PLACEBO-CONTROLLED TRIAL; GROWTH-HORMONE TREATMENT; CEREBRAL BLOOD-FLOW; ROSTRAL VENTROMEDIAL MEDULLA; SPINOTHALAMIC TRACT NEURONS; IMMUNOREACTIVE SUBSTANCE-P; BIOGENIC-AMINE METABOLITES; CEREBROSPINAL-FLUID LEVELS;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The fibromyalgia syndrome (FMS) is the most frequent cause of chronic, wide spread pain. This review, which is targeted at the psychiatry and psychopharmacology communities, summarizes the state-of-the-art as it relates to both the pathophysiology and treatment of FMS. Toward this end, the anatomy and physiology of pain pathways are summarized, followed by a review of the altered biology of pain processing, neurotransmitter function, and neuroendocrine systems in FMS. The categories of current drugs employed to treat the disorder are detailed, along with a critical review of the literature supporting such use. Psychopharmacology Bulletin. 2007;40(4):24-67.
引用
收藏
页码:24 / 67
页数:44
相关论文
共 50 条
  • [21] Fibromyalgia in primary antiphospholipid (Hughes) syndrome
    Costa, S. P.
    Lage, L. V.
    Henrique da Mota, L. M.
    de Carvalho, J. F.
    [J]. LUPUS, 2011, 20 (11) : 1182 - 1186
  • [22] Fibromyalgia syndrome - Novel therapeutic targets
    Ablin, Jacob N.
    Buskila, Dan
    [J]. MATURITAS, 2013, 75 (04) : 335 - 340
  • [23] Neurophysiopathogenesis of Fibromyalgia Syndrome: A Unified Hypothesis
    Russell, I. Jon
    Larson, Alice A.
    [J]. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2009, 35 (02) : 421 - +
  • [24] Implicit Memory Function in Fibromyalgia Syndrome
    Duschek, Stefan
    Werner, Natalie S.
    Winkelmann, Andreas
    Wankner, Sarah
    [J]. BEHAVIORAL MEDICINE, 2013, 39 (01) : 11 - 16
  • [25] Possible Molecular Mediators Involved and Mechanistic Insight into Fibromyalgia and Associated Co-morbidities
    Singh, Lovedeep
    Kaur, Anudeep
    Bhatti, Manpreet S.
    Bhatti, Rajbir
    [J]. NEUROCHEMICAL RESEARCH, 2019, 44 (07) : 1517 - 1532
  • [26] Fibromyalgia syndrome. New developments in pharmacotherapy
    Harten, P.
    [J]. ZEITSCHRIFT FUR RHEUMATOLOGIE, 2008, 67 (01): : 75 - 82
  • [27] The evaluation in terms of sarcopenia of patients with fibromyalgia syndrome
    Koca, Irfan
    Savas, Esen
    Ozturk, Zeynel Abidin
    Boyaci, Ahmet
    Tutoglu, Ahmet
    Alkan, Samet
    Yildiz, Hamit
    Kimyon, Gezmis
    [J]. WIENER KLINISCHE WOCHENSCHRIFT, 2016, 128 (21-22) : 816 - 821
  • [28] Discriminative Value of Tender Points in Fibromyalgia Syndrome
    Tastekin, Nurettin
    Uzunca, Kaan
    Sut, Necdet
    Birtane, Murat
    Mercimek, Oznur Berke
    [J]. PAIN MEDICINE, 2010, 11 (03) : 466 - 471
  • [29] Fibromyalgia: a complex syndrome requiring a multidisciplinary approach
    Spaeth, Michael
    Briley, Mike
    [J]. HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2009, 24 : S3 - S10
  • [30] Complementary Therapies for Fibromyalgia Syndrome - A Rational Approach
    Saad, Marcelo
    de Medeiros, Roberta
    [J]. CURRENT PAIN AND HEADACHE REPORTS, 2013, 17 (08)